A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

Morris D. Groves,Vinay K. Puduvalli,Susan M. Chang,Charles A. Conrad,Mark R. Gilbert,Ivo W. Tremont-Lukats,Ta Jen Liu,Pamela Peterson,David Schiff,Timothy F. Cloughesy,Patrick Y. Wen,Harry S. Greenberg,Lauren E. Abrey,Lisa M. DeAngelis,Kenneth R. Hess,Kathleen R. Lamborn,Michael D. Prados,Alfred Yung

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

2007

Morris D. Groves
Vinay K. Puduvalli
Susan M. Chang
Charles A. Conrad
Mark R. Gilbert
Ivo W. Tremont-Lukats
Ta Jen Liu
Pamela Peterson
David Schiff
Timothy F. Cloughesy
Patrick Y. Wen
Harry S. Greenberg
Lauren E. Abrey
Lisa M. DeAngelis
Kenneth R. Hess
Kathleen R. Lamborn
Michael D. Prados
Alfred Yung

Background Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM).

Keywords:

Temozolomide
Cancer research
Clinical trial
Karnofsky Performance Status
Pathology
Glioblastoma
Thalidomide
Progression-free survival
North American Brain Tumor Consortium
Brain tumor
Medicine
Interleukin 8
recurrent glioblastoma
Vascular endothelial growth factor
Basic fibroblast growth factor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations